# Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)

> **NCT06034886** · — · AVAILABLE · sponsor: **Biohaven Pharmaceuticals, Inc.**

## Conditions studied

- SCA
- Spinocerebellar Ataxias

## Interventions

- **DRUG:** Troriluzole

## Key facts

- **NCT ID:** NCT06034886
- **Lead sponsor:** Biohaven Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** AVAILABLE
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2026-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06034886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06034886, "Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06034886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*